Jasper Hellweg
Stock Analyst at Argus Research
(2.11)
# 2,966
Out of 5,078 analysts
89
Total ratings
47.89%
Success rate
3.65%
Average return
Main Sectors:
Stocks Rated by Jasper Hellweg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BAX Baxter International | Downgrades: Hold | n/a | $18.84 | - | 3 | Oct 31, 2025 | |
| ZTS Zoetis | Reiterates: Buy | $190 | $124.44 | +52.68% | 7 | Sep 9, 2025 | |
| BIIB Biogen | Downgrades: Hold | n/a | $180.18 | - | 4 | Apr 4, 2025 | |
| UTHR United Therapeutics | Maintains: Buy | $360 → $400 | $474.14 | -15.64% | 7 | Oct 31, 2024 | |
| ILMN Illumina | Upgrades: Buy | $150 | $127.55 | +17.60% | 7 | Aug 28, 2024 | |
| SNY Sanofi | Maintains: Buy | $55 → $60 | $49.85 | +20.36% | 2 | Jul 26, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $1,060 → $1,170 | $742.00 | +57.68% | 9 | Jun 25, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $465 → $550 | $433.15 | +26.98% | 7 | Jun 17, 2024 | |
| AZN AstraZeneca | Maintains: Buy | $80 → $85 | $90.17 | -5.73% | 3 | May 30, 2024 | |
| NVO Novo Nordisk | Maintains: Buy | $115 → $125 | $47.43 | +163.55% | 1 | Feb 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $160 → $140 | $24.06 | +481.88% | 4 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $224.37 | - | 2 | Apr 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $26.88 | - | 1 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $290 | $225.63 | +28.53% | 4 | Sep 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $100 | $69.99 | +42.88% | 3 | Jun 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $270 → $295 | $265.93 | +10.93% | 4 | May 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $10.85 | - | 3 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $135 | $182.55 | -26.05% | 5 | Oct 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $13.61 | - | 2 | Apr 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $208.67 | - | 3 | Apr 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $28.60 | - | 4 | Oct 30, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $150 → $155 | $500.31 | -69.02% | 3 | Nov 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $90 | $63.24 | +42.31% | 1 | Sep 19, 2018 |
Baxter International
Oct 31, 2025
Downgrades: Hold
Price Target: n/a
Current: $18.84
Upside: -
Zoetis
Sep 9, 2025
Reiterates: Buy
Price Target: $190
Current: $124.44
Upside: +52.68%
Biogen
Apr 4, 2025
Downgrades: Hold
Price Target: n/a
Current: $180.18
Upside: -
United Therapeutics
Oct 31, 2024
Maintains: Buy
Price Target: $360 → $400
Current: $474.14
Upside: -15.64%
Illumina
Aug 28, 2024
Upgrades: Buy
Price Target: $150
Current: $127.55
Upside: +17.60%
Sanofi
Jul 26, 2024
Maintains: Buy
Price Target: $55 → $60
Current: $49.85
Upside: +20.36%
Regeneron Pharmaceuticals
Jun 25, 2024
Maintains: Buy
Price Target: $1,060 → $1,170
Current: $742.00
Upside: +57.68%
Vertex Pharmaceuticals
Jun 17, 2024
Maintains: Buy
Price Target: $465 → $550
Current: $433.15
Upside: +26.98%
AstraZeneca
May 30, 2024
Maintains: Buy
Price Target: $80 → $85
Current: $90.17
Upside: -5.73%
Novo Nordisk
Feb 1, 2024
Maintains: Buy
Price Target: $115 → $125
Current: $47.43
Upside: +163.55%
Sep 13, 2023
Maintains: Buy
Price Target: $160 → $140
Current: $24.06
Upside: +481.88%
Apr 5, 2023
Downgrades: Hold
Price Target: n/a
Current: $224.37
Upside: -
Jan 27, 2022
Downgrades: Hold
Price Target: n/a
Current: $26.88
Upside: -
Sep 10, 2021
Maintains: Buy
Price Target: $260 → $290
Current: $225.63
Upside: +28.53%
Jun 9, 2021
Upgrades: Buy
Price Target: $100
Current: $69.99
Upside: +42.88%
May 20, 2021
Maintains: Buy
Price Target: $270 → $295
Current: $265.93
Upside: +10.93%
May 5, 2021
Downgrades: Hold
Price Target: n/a
Current: $10.85
Upside: -
Oct 21, 2020
Upgrades: Buy
Price Target: $135
Current: $182.55
Upside: -26.05%
Apr 17, 2020
Downgrades: Hold
Price Target: n/a
Current: $13.61
Upside: -
Apr 6, 2020
Downgrades: Hold
Price Target: n/a
Current: $208.67
Upside: -
Oct 30, 2019
Downgrades: Hold
Price Target: n/a
Current: $28.60
Upside: -
Nov 6, 2018
Maintains: Buy
Price Target: $150 → $155
Current: $500.31
Upside: -69.02%
Sep 19, 2018
Maintains: Buy
Price Target: $85 → $90
Current: $63.24
Upside: +42.31%